BDNF and Alzheimer disease: To support this hypothesis in the current study, our primary objectives are to (1) assess the relationships among proBDNF and BDNF with a battery of cytokines, growth factors, and T cell and B cell subsets before and after 12 months of supplementation with APMC and (2) evaluate if the 5000 pg/mL cutoff value for BDNF that we previously found relevant to discriminate levels of cognitive functioning in this AD population will be applicable/useful for distinguishing different values in the biomarkers of interest.